| Document |
Document Title |
|
JP2023073244A |
To provide a glycopeptide composition having an intestinal environment improving effect surpassing that of κ-casein glycomacropeptide, and a method for producing the glycopeptide composition.An intestinal environment improvement composi...
|
|
JP7278775B2 |
The present invention relates to a preparation method of a long-chain compound, which includes the following steps: (1) carrying out condensation reaction on H-R 2 and R 5 N-Glu(OR 4 )-OR 3 , wherein, R 3 is a carboxyl protecting group, ...
|
|
JP2023519247A |
The tumor stroma, which makes up the majority of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here we focus specifically on a subpopulation of stromal cells known as cancer-associated ...
|
|
JP2023518902A |
Non-toxic targeted poly-β-aminoesters (PBAEs) are synthesized by binding to target sites using click chemistry. Click chemistry uses dienophiles such as strained alkene rings and dienes such as tetrazines to rapidly attach target moieti...
|
|
JP2023518413A |
In some embodiments, the present disclosure provides staple peptides and compositions thereof. In some embodiments, provided peptides can bind to the estrogen receptor and modulate its function. In some embodiments, this disclosure provi...
|
|
JP2023517779A |
The present disclosure relates to the field of commercial scale production and processing of pharmaceutical liquid or solid compositions derived from insects, the compositions comprising purified recombinant proteins, vaccines, antibodie...
|
|
JP2023516855A |
The present disclosure relates to the field of polymer chemistry, and more particularly to multi-block copolymers comprising poly(sarcosine) blocks and D, L-mixed poly(amino acid) blocks and uses thereof. The present disclosure is direct...
|
|
JP2023513830A |
The present invention relates to the field of cell culture and recombinant protein or recombinant virus production in mammalian cells. The present invention particularly relates to novel feed media that provide lactate and high concentra...
|
|
JP2023510741A |
G.1is a folate radical, an antifolate radical, or a folate analogue radical; L is a linker; and G2is the radical of the steroid, formula (I): G1-LG2or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof; ...
|
|
JP2023033802A |
To provide a method for producing proteoglycan derived from salmon, which contains sodium of 7 wt.% or more and calcium of 0.7 wt.% or less.An aqueous solution of salmon-derived proteoglycan is brought into contact with 50 mM or more of ...
|
|
JP2023031725A |
To provide Rab39B FRET biosensors.The present invention provides a single-molecule FRET biosensor based on the principle of fluorescence resonance energy transfer, the single-molecule FRET biosensor comprising one of an acceptor fluoresc...
|
|
JP2023508440A |
The present invention provides methods of making PNA oligomers. More specifically, it involves reacting a PNA block with a PNA block in solution phase to produce a PNA oligomer, which is a simple solution process to produce the desired P...
|
|
JP2023507831A |
Site-specific modification of proteins is desirable in biotechnological applications such as biopharmaceuticals, immunotherapy, vaccines and is useful in chemical biology. Gluconoylation is a non-enzymatic, covalent, post-translational m...
|
|
JP2023507409A |
The present invention provides a non-toxic method for producing cyclic peptides in mammalian cells, comprising the steps of: a) introducing a vector into the mammalian cell, wherein the vector comprises a C-terminal intein domain introdu...
|
|
JP2023504873A |
The present invention relates to the field of human therapy. In particular, the present invention provides novel synthetic peptide-based chloride ion transporters and compositions thereof to treat, reduce, inhibit, or control CFTR-mediat...
|
|
JP2023503790A |
The present invention provides a method of treatment comprising administering an AQGV peptide, or a functional analog thereof, to a human subject, optionally having renal impairment, wherein the treatment of administering the AQGV peptid...
|
|
JP2023503373A |
A compound of formula (I) AQB I, wherein Q represents a structural fragment of formula (II), the wavy line and m have the meaning given in the specification, and A and B are The peptide component of the amino acid sequence [W-Lys-X1-Ser-...
|
|
JP2023501720A |
Among other things, this disclosure provides techniques for site-specifically conjugating various moieties of interest to targeting agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conj...
|
|
JP2023005522A |
To provide a novel polymer composition exhibiting osmoregulatory activity, or particularly, an osmoregulator which can inhibit protein alteration, etc. in lower concentrations.An osmoregulator comprises a polymer composition including a ...
|
|
JP7204720B2 |
The invention relates to chitin, a hydrolysate and a method for the production of at least one desired product from insects. More specifically, the invention relates to a method for the production of at least one desired product from ins...
|
|
JP2022191408A |
To provide lipid conjugates for enhanced delivery of cargo to the lymph nodes.The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo (such as a molecular adjuvan...
|
|
JP2022553367A |
Applicants have shown that the peptide of SEQ ID NO: 1 (WKDEAGKPLVK) mediates changes in key biomarker activities associated with NASH (Table 1) and that it can penetrate HepG2 hepatocytes in a hepatocyte permeation assay (Fig. 1) was di...
|
|
JP2022553318A |
The present invention provides a phosphorus-containing compound, its production method and its use. The phosphorus-containing compound of the present invention has the following structure. [Chemical 1] A definition of each group is given...
|
|
JP2022552137A |
The present invention describes a method to generate a bacterial-derived chimeric aminoacyl-tRNA synthetase (aaRS) that exhibits optimal activity and high thermostability. These chimeric aaRSs can be made more aggressive to generate a wi...
|
|
JP2022182687A |
To provide a peptide compound containing an optimized peptide ligand having isoquercitrin αvβ5 binding capacity.A peptide compound is represented by the following formula (I). In the formula (I), X1 is a peptide containing amino acid r...
|
|
JP7186165B2 |
Provided are a compound represented by formula I that can be used in nucleic acid photoreaction techniques, and a photoreactive crosslinking agent comprising the compound.
|
|
JP2022551061A |
The present invention provides antibody-drug conjugates targeting lysosomes and applications thereof. The antibody-drug conjugate is Drn1AbOn2wherein Dr is a drug, Ab is an antibody, and O is a lysosome-directed small molecule or a funct...
|
|
JP2022550901A |
Novel nucleic acid delivery systems comprising linear histidine-lysine-rich cysteine-containing peptides and tetra-antennary histidine-lysine-rich polypeptides with targeting functionality are provided. Delivery systems include nucleic a...
|
|
JP7176958B2 |
The present invention relates to the generation of lead-212 for therapeutic use. Specifically, are methods related to the generation of lead-212 based radio labelled proteins, such as radioimmunoconjugates, embodiments of the present inv...
|
|
JP2022548841A |
Methods and apparatus are provided for designing sequence-defined biomolecules, such as proteins, using data-driven evolution-based processes. To design proteins, iterative methods based on a combination of unsupervised sequence-based mo...
|
|
JP2022548320A |
The present invention provides agents and compositions for modulating (e.g., enhancing or reducing expression) the expression of the apolipoprotein B (APOB) gene by targeting the APOB expression control region, and APOB Methods of its us...
|
|
JP2022172128A |
To provide a peptide and a protein-based therapeutic drug with improved pharmaceutical properties.A peptide product includes surfactant X covalently bonded to a peptide, where the peptide includes linker amino acid U and at least one oth...
|
|
JP2022167698A |
To provide a PEG-modified protein having reduced immunogenicity.A PEG-modified protein is represented by the formula (1) [where P is a protein residue, A is a group having a polyethylene glycol residue with a molecular weight of 1000-500...
|
|
JP2022545765A |
The present invention relates to known intermediate filament-derived peptides capable of inducing cell death and/or stimulating inflammatory cytokine secretion in metazoan cells. The peptide has a first region of 'n' amino acids (where '...
|
|
JP7160294B1 |
An object of the present invention is to provide a method for recovering microparticles or extracellular vesicles covered with a lipid bilayer membrane that can sufficiently separate extracellular vesicles. A method for collecting microp...
|
|
JP2022544647A |
The present invention describes uPAR-targeting peptide conjugates comprising a covalently linked fluorophore, a uPAR-binding peptide and a linker group, wherein the uPAR-targeting peptide conjugates are used to treat cancer tumors or met...
|
|
JP2022160632A |
To provide methods and compositions for enhancing the immunogenicity of polypeptides.Provided is a composition comprising a tagged polypeptide consisting of a polypeptide, a spacer peptide composed of 0 to 2 amino acids attached to the e...
|
|
JP2022159997A |
To provide a method for recovering valuable metals in a solubilized state by a simple process from water to be treated that contains valuable metals.A method for recovering valuable metals includes: a step in which (a) a valuable metal-r...
|
|
JP2022543842A |
The present disclosure relates to implantable structures designed to deliver antigenic therapeutic reagents to a subject while protecting against host immune responses. In certain embodiments, the structures are designed to degrade over ...
|
|
JP2022543467A |
The present disclosure provides targeted cell delivery lipid nanostructures that enable enhanced delivery of agents, e.g., nucleic acids, e.g., therapeutic and/or prophylactic RNA, to target cells, particularly hepatocytes and/or splenoc...
|
|
JP7149929B2 |
The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-li...
|
|
JP2022542286A |
In the present invention, a first peptide ligand that binds to a component present on cancer cells is conjugated via a linker to two or more second peptide ligands that bind to a component present on immune cells. Heterotandem bicyclic p...
|
|
JP2022541911A |
The present invention provides analytical tools for the characterization of bioconjugates, in particular for determination of glycosylation levels, and methods for absolute quantification of glycosylation sequences, as well as sequences ...
|
|
JP2022135720A |
To provide a new extracellular electron transfer material.An extracellular electron transfer material is composed of a material containing a protein that contains sulfur and a β sheet structure.SELECTED DRAWING: None
|
|
JP2022538784A |
Compositions, methods, cells, engineered microorganisms and kits for increasing the production of proteins or polypeptides comprising one or more unnatural amino acids are disclosed herein. Further provided are compositions, cells, engin...
|
|
JP2022122912A |
To provide micelles that enable increased blood retention and efficient release of proteins in acidic conditions, for increased therapeutic efficacy of therapeutic proteins.Provided is a polymer complex comprising a protein and a block c...
|
|
JP2022536695A |
The present disclosure relates to immunotherapeutic polypeptides comprising neoepitopes, antigen-presenting cells comprising immunotherapeutic polypeptides, and pharmaceutical compositions comprising immunotherapeutic polypeptides. Also ...
|
|
JP7120765B2 |
In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and ...
|
|
JP2022534245A |
A polymer comprising a hydrolyzable polymer backbone, wherein the polymer backbone has (i) monomer units having side chains comprising hydrophobic groups, (ii) monomer units having side chains comprising oligoamines or polyamines; (iii) ...
|
|
JP2022532409A |
The present invention relates to immunogenic peptides containing oxidoreductase motifs, including T cell epitopes and modified cysteines, and their use in regulating the immune response in a subject.
|
